drugs

QARI ® - Rufloxacin

QARI ® is a drug based on Rufloxacin hydrochloride

THERAPEUTIC GROUP: Antibacterial for systemic use

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications QARI ® - Rufloxacin

QARI ® is used clinically in the treatment of infections of the lower respiratory tract and urinary tract supported by microorganisms sensitive to Rufloxacin.

The antibiotic itself has proved invaluable in pre-operative antibiotic prophylaxis.

Mechanism of action QARI ® - Rufloxacin

Rufloxacin, the active ingredient of QARI ®, is an antibiotic belonging to the fluoroquinolone category and therefore has a broad spectrum of direct action against different pathogenic species.

Its therapeutic activity is due to its ability to permeate the walls and membranes of bacterial cells by inhibiting enzymes such as DNA gyrase, normally involved in the mechanisms of regulation of genomic replication, and therefore fundamental for the proliferation and survival of the microorganism.

In the face of a bactericidal mechanism, Rufloxacin is also endowed with excellent pharmacokinetic properties which allow the active ingredient taken orally to be rapidly absorbed at the gastrointestinal level and efficiently distributed among the various tissues, with particular tropism for the liver and genitourinary .

The long half-life, estimated over 24 hours, also allows daily drug administration, which makes therapy with QARI ® decidedly simpler and more complete.

At the end of its activity, Rufloxacin is mainly eliminated via the kidney, although a small part is metabolised to the hepatic level and excreted via the bile

Studies carried out and clinical efficacy

RUFLOXACINE AND CENTRAL NERVOUS SYSTEM INFECTIONS

Antimicrob Agents Chemother. 2000 Jan; 44 (1): 73-7.

Interesting study that demonstrates how Rufloxacin can permeate inflamed meninges reaching the cerebrospinal fluid and thus performing a therapeutic action even at the level of the central nervous system.

THE EFFECTIVENESS OF RUFLOXACINE AT SUBTERAPEUTIC DOSES

Antimicrob Agents Chemother. 1999 May; 43 (5): 1013-9.

Pharmacokinetic work demonstrating the potential antibacterial activity of Rufloxacin, taken at sub-therapeutic doses, especially useful in the treatment of uncomplicated urinary tract lower infections.

RUFLOXACINE IN PATIENTS WITH CANCER

J Antimicrob Chemother. 1996 Nov; 38 (5): 839-47.

Study demonstrating that daily administration of Rufloxacin may be effective in preventing infections even in cancer patients and therefore significantly immunocompromised.

Method of use and dosage

QARI ®

Rufloxacin hydrochloride 200 mg coated tablets

Although daily administration of Rufloxacin 200-400 mg is generally effective, it is essential that doses and timing of intake are defined by your doctor based on your physiopathological characteristics and on the severity of the present clinical picture.

An adjustment of the dosages used should also be provided for patients suffering from kidney disease or in elderly patients.

Warnings QARI ® - Rufloxacin

Treatment with QARI ® should be preceded and accompanied by medical supervision, in order to limit the possible appearance of clinically relevant adverse reactions, while maintaining high therapeutic efficacy.

It is worth recalling the potential risks to which elderly, nephropathic patients with a history of neurological and cardiac pathologies are exposed, subjected simultaneously to therapy with QARI ®.

For the same reason it would also be important to consider the potential side effects of drug therapy with Rufloxacin for tendons and skin subjected to ultraviolet radiation, given the high photosensitising power of the drug.

Prolonged use of QARI ®, as well as that of other antibiotics, could facilitate the spread of multiresistant microbial strains responsible for particularly serious clinical pictures.

PREGNANCY AND BREASTFEEDING

Given the absence of studies able to fully characterize the safety profile of Rufloxacin for the fetus and infant, it would be advisable to avoid taking QARI ® during pregnancy and in the subsequent breastfeeding period.

Interactions

The patient taking QARI ® should pay particular attention to the simultaneous intake of antacids, quinolones and NSAIDs due to the risk of unpleasant adverse reactions rather than significant alterations of the therapeutic properties of the drug.

Contraindications QARI ® - Rufloxacin

The use of QARI ® is contraindicated in patients hypersensitive to the active ingredient or to any of its excipients, in children, in patients predisposed or with a previous history of neurological and cardiac pathologies.

Undesirable effects - Side effects

Rufloxacin-based therapy could lead to the appearance of side effects such as: cramping abdominal pains, nausea, heartburn, dyspepsia, diarrhea and vomiting, headache, agitation, anxiety, dizziness, insomnia and fatigue and only rarely from hypersensitivity reactions sometimes serious from clinical point of view.

Side effects at the tendon level were very rare, affecting mostly high-risk patients.

Note

QARI ® is a prescription-only drug.